Key Points Viking Therapeutics' stock dropped after a capital raise, not due to trial results. The company raised more capital than initially planned, indicating strong demand. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) stock declined by 14.5% in early morning trading today, a week after the company reported top-line results from a maintenance study of its key weight-loss drug, VK2735. However, don't panic. Today's move is not directly related to the results released a couple of days ago.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.